business / news / / Seeking Alpha
Amgen: Who Leads Obesity And IMIDs Allka Research 3.35K Followers Comment (1) Summary Amgen Inc.
Amgen is actively seeking to enter the GLP-1 obesity drug market dominated by Eli Lilly.
KEY POINTS
- Both Amgen and Eli Lilly have notable gaps in their drug portfolios compared to each other.
- Amgen and Eli Lilly are leading competitors in the immune-mediated inflammatory diseases treatment sector.
- The article provides a comparative long-term investment outlook for Amgen versus Eli Lilly.
COMPANIES
Summarized by Newsio from Seeking Alpha. How we summarize →